Upon publication of the original article [1], it was noticed that Fig. 5 contained an error. The Fig. 5e (middle) for CD34 area fraction (%) data was erroneously included during the drafting of the manuscript. This has now been acknowledged and corrected in this erratum. The correct Fig. 5 is shown below.
Fig. 5
RERG inhibited the tumorigenesis and angiogenesis of NPC in vivo. Eight male BALB/c athymic nu/nu mice injected with 2 × 106 cells. a Growth curve of tumors in nude mice. Tumor volume was measured every 3 days after inoculation. b Image of nude mouse tumors derived from HK1 cells stably transfected with RERG or empty vector. Arrows indicate positions and locations of tumors. c The average weights of tumors in nude mice. d Representative photographs of H&E staining, IHC analyses of the expression of RERG and immunofluorescence analyses of the expression of CD34 (red), α-SMA (green) in tumors from nude mice. Nuclei were counterstained by DAPI (blue) in the merged pictures of immunofluorescence analyses. Original magnification is × 200. Bar represents 50 μm. eLeft, IHC scores of RERG in tumors from nude mice. Middle and right, for immunofluorescence analyses, graphs represent average area fraction (%) ± SD of microvessels/field by CD34 and α-SMA area fraction (%) in tumors from nude mice analyzed by Image J. Data are shown as means ± SD. **: P < 0.01, ***: P < 0.001 by Mann-Whitney U test or Student’s t-test
×
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
